Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Italy / NCT07317011
Recruiting Observational

"Referral Attivo" Delta, Dallo Screening Alla Presa in Carico.

NCT07317011 · tracked via the Priya Life Science Italy tracker
Sponsor
FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS
Phase
Observational
Started
2025-10-01
Last updated
2026-07-09

Condition(s) studied

Hepatitis, Delta

Study summary

The aim of the "Active Delta Referral" Project is to estimate the prevalence of anti-HDV positivity among HBsAg-positive patients hospitalized in the Department of Medicine at ASST Papa Giovanni XXIII in Bergamo, as well as among patients at the SerD and the Prison Healthcare Unit of the same ASST, following the introduction of the new methodology in 2025, and to compare these findings with existing estimates for outpatients.

Eligibility

Sex
ALL
Min age
18 Years
Max age
100 Years
Healthy volunteers
No
Inclusion Criteria: * Patients aged ≥18 years. * Hospitalized at the Department of Medicine of ASST Papa Giovanni XXIII in Bergamo, or attending the SerD or the Penitentiary Health Service of Bergamo. * HBsAg positivity. * Obtaining informed consent. Exclusion Criteria: * Lack of informed consent

Primary outcome measure(s)

  • Percentage of anti-HDV positive — At diagnosis during the baseline
    Estimate the percentage of anti-HDV positive individuals among HBsAg positive hospitalized patients

Trial sites (1)

FacilityCityRegionStatus
Asst Papa Giovanni Xxiii Bergamo Italy Recruiting

More FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS trials in Italy

A ELN-Multicenter Study on Phenotypic Evolution and Clinical Outcomes Recruiting
Observational Study on the Use of Ropeginterferon Alfa-2b in Polycythemia Vera (ROPEG-PV) Recruiting
Transitional ePRO Diary Liver (Transitional-ePRO) Recruiting
ePro Diary - HDV ( MACROLIVER ) Recruiting
Clinical Epidemiology in Contemporary Patients With Myelofibrosis. Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07317011 on ClinicalTrials.gov ↗ ← All trials in Italy